Pipeline Web Pipeline Mobile


VLS-101 is an investigational antibody-drug conjugate (ADC) targeting cancers that commonly express receptor tyrosine kinase-like orphan receptor 1 (ROR1). VLS-101 comprises a humanized monoclonal antibody targeting ROR1, a proteolytically cleavable linker, and the anti-microtubule cytotoxin, monomethyl auristatin E (MMAE). The linker-toxin combination (known as vedotin) is already used in available ADCs that target other tumor antigens.

VLS-101 binds to ROR1-expressing tumor cells, resulting in internalization of the ADC-ROR1 complex. Within these tumor cells, lysosomal enzymes release the cytotoxin (ie, MMAE). Binding of MMAE to tubulin disrupts the microtubule network within the tumor cell, subsequently inducing cell-cycle arrest and apoptotic tumor cell death.

VLS-101 has demonstrated in vivo activity, including complete regression of tumors, in nonclinical models of hematologic malignancies and solid tumors.

A Phase 1, first-in-human clinical trial of VLS-101 monotherapy in patients with hematologic cancers is ongoing. Further details are available at ClinicalTrials.gov.

Next-Generation ROR1-directed Antibody-Drug Conjugates

VelosBio is evaluating next-generation, investigational antibody-drug conjugates (ADCs) by testing multiple combinations of stable conjugations, cleavable linkers, and payloads. The goal is to develop ROR1-targeted ADCs that are broadly active and well tolerated and that complement VLS-101 by offering alternative methods of potential tumor cell killing.

ROR1-directed Bispecific Antibodies

VelosBio is developing investigational ROR1-targeting bispecific antibodies (BiAbs) that are designed to harness the immune system to kill tumors. Anti-ROR1 BiAbs have been generated in multiple formats that bind to CD3 receptors on T cells or CD16 receptors on natural killer cells, thereby attracting these immune cells to destroy the cancer.



Clinical Trials Triangle Copy
Approach mob

Now Leaving The VelosBio Site.

VelosBio Inc. is now a wholly-owned subsidiary of Merck & Co., Inc. (Kenilworth, New Jersey USA)

CLICK TO VISIT www.merck.com